EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation

Brooks D Cash, Amol Sharma iD, Anna Walker, Adam P Laitman, Lin Chang iD

Neurogastroenterology & Motility · 2023-09 · 35 (9)

DOI: 10.1111/nmo.14632 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 18.06.2023. Verfasst von Brooks D Cash und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Salix Pharmaceuticals, Synergy Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS‐C) often experience severe symptoms. The current aim was to evaluate plecanatide in adults with CIC or IBS‐C with severe constipation.

Methods

Data were analyzed post hoc from randomized, placebo‐controlled trials (CIC [ n = 2], IBS‐C [ n = 2]) of plecanatide 3 mg, 6 mg, or placebo administered for 12 weeks. Severe constipation was defined as no complete spontaneous bowel movements (CSBMs) and an average straining score ≥3.0 (CIC; 5‐point scale) or ≥8.0 (IBS‐C; 11‐point scale) during a 2‐week screening. Primary efficacy endpoints were durable overall CSBM responders (CIC: ≥3 CSBMs/week, plus increase from baseline of ≥1 CSBM/week, for ≥9 of 12 weeks, including ≥3 of the last 4 weeks) and overall responders (IBS‐C: ≥30% reduction from baseline in abdominal pain and ≥1 CSBM/week increase for ≥6 of 12 weeks). Key Results Severe constipation was observed in 24.5% (646/2639) and 24.2% (527/2176) of CIC and IBS‐C populations, respectively. The CIC durable overall CSBM response rate (plecanatide 3 mg, 20.9%; plecanatide 6 mg, 20.2%; placebo, 11.3%) and IBS‐C overall response rate (plecanatide 3 mg, 33.0%; plecanatide 6 mg, 31.0%; placebo, 19.0%) were significantly greater with plecanatide versus placebo ( p ≤ 0.01 for all). Median time to first CSBM in CIC and IBS‐C populations were significantly shorter with plecanatide 3 mg versus placebo ( p = 0.01 for both). Conclusions and Inferences Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS‐C.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeHumansAdultPeptidesConstipationNatriuretic PeptidesTreatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

Trulanceconstipationguanylyl cyclase C agonistsirritable bowel syndromeplecanatide

Substanzen

plecanatidePeptidesNatriuretic Peptides

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA.
  • Division of Gastroenterology & Hepatology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Salix Pharmaceuticals, Bridgewater, New Jersey, USA.
  • Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.

ORCID-Profile: Amol Sharma, Lin Chang

Förderung

  • Salix Pharmaceuticals
  • Synergy Pharmaceuticals

Zitieren

APA

Cash, B. D., Sharma, A., Walker, A., Laitman, A. P., & Chang, L. (2023). Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility, 35(9). https://doi.org/10.1111/nmo.14632

Vancouver

Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation. Neurogastroenterology & Motility. 2023;35(9). doi:10.1111/nmo.14632

BibTeX
@article{Cash2023,
  author = {Cash, Brooks D and Sharma, Amol and Walker, Anna and Laitman, Adam P and Chang, Lin},
  title = {Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation},
  journal = {Neurogastroenterology & Motility},
  year = {2023},
  volume = {35},
  number = {9},
  doi = {10.1111/nmo.14632}
}
Kostenlos starten →